在204个国家和地区的胃潰瘍疾病负担,趋势和不平等,1990-2019:基于人口的研究研究
Zhongmian Zhang1, Weitian Yan2, Xiyan Zhang1
1Department of Gastroenterology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Therapeutic advances in gastroenterology
|November 29, 2023
概括
全球胃病发病率,残疾和死亡率在1990年至2019年期间显著下降. 胃病负担的下降伴随着全球不平等的减少.
科学领域:
- 流行病学 流行病学
- 全球健康 全球健康
- 公共卫生 公共卫生
背景情况:
- 胃潰瘍疾病 (PUD) 造成全球健康的重大威脅,有助於住院治療和醫療資源使用.
- 了解PUD的全球负担,趋势和不平等对于公共卫生干预至关重要.
研究的目的:
- 描述胃病 (PUD) 的全球负担,发病率,残疾调整寿命年 (DALYs) 和死亡率.
- 从1990年到2019年分析PUD的趋势和不平等情况.
- 评估PUD趋势与社会经济因素之间的关联.
主要方法:
- 2019年全球疾病,伤害和风险因素负担研究的二次分析.
- 提取了针对PUD的年龄标准化发病率 (ASIR),DALY率 (ASDR) 和死亡率 (ASMR).
- 根据社会人口统计指数 (SDI) 计算估计年百分比变化 (EAPC) 和量化跨国不平等.
主要成果:
- 从1990年到2019年,全球ASIR每年下降了1.42%,ASDR下降了3.47%,ASMR下降了2.55%.从1990年到2019年,全球ASIR每年下降了1.42%,ASDR下降了3.47%,ASMR下降了2.55%.
- 在1990年至2019年期间,PUD死亡率几乎下降了一半.
- 与社会人口统计指数 (SDI) 相关的DALY不平等程度显著下降,从1990年的每10万人口中的190.43个下降到2019年的62.85个.
结论:
- 全球胃潰瘍疾病的罹患率和死亡率在1990年至2019年之間大幅下降.
- 观察到与SDI相关的不平等程度大幅减少,与整体社会经济和健康状况的改善保持一致.
- 这些发现突显了在管理PUD负担和减少差异方面全球健康方面的积极收益.
更多相关视频
03:47Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography
Published on: November 1, 2024
204
04:56Detection of Helicobacter pylori Infection and Antibiotic Resistance via Stool Quantitative Polymerase Chain Reaction Analysis
Published on: May 16, 2025
318
相关概念视频
01:30Peptic Ulcer Disease I: Introduction
178
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
178
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
131
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
131
01:28Peptic Ulcer Disease II: Pathophysiology
451
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
451
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
435
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
435
01:26Peptic Ulcer Disease IV: Management
95
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
95
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
449
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
449